We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF...
TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two...
Suspension de la négociation par l'Organisme canadien de réglementation des investissements - CZO Canada NewsWire VANCOUVER, BC, le 3 juin 2024 VANCOUVER, BC, le 3 juin 2024 /CNW/...
Canadian Investment Regulatory Organization Trading Halt - CZO Canada NewsWire VANCOUVER, BC, June 3, 2024 VANCOUVER, BC, June 3, 2024 /CNW/ - The following issues have been halted by...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale...
– 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the...
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased...
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.225 | 0.225 | 0.225 | 0 | 0 | CS |
4 | 0 | 0 | 0.225 | 0.225 | 0.225 | 0 | 0 | CS |
12 | 0 | 0 | 0.225 | 0.225 | 0.225 | 0 | 0 | CS |
26 | -0.005 | -2.17391304348 | 0.23 | 0.295 | 0.225 | 17801 | 0.25035717 | CS |
52 | -0.155 | -40.7894736842 | 0.38 | 0.4 | 0.15 | 30443 | 0.26087255 | CS |
156 | -0.395 | -63.7096774194 | 0.62 | 0.82 | 0.15 | 30983 | 0.47676536 | CS |
260 | -0.135 | -37.5 | 0.36 | 0.98 | 0.14 | 38084 | 0.5044868 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions